Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020
Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, discusses the five-year follow-up of the ECHELON-2 study investigating brentuximab vedotin with chemotherapy in peripheral T-cell Lymphoma (PTCL) as presented at the 62nd ASH Annual Meeting & Exposition
Radhakrishnan Ramchandren, MD, elaborates on the five-year follow-up data from ECHELON-1
Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, shares details from the five-year follow-up of the ECHELON-1 study investigating brentuximab vedotin with chemotherapy in stage III/IV classical Hodgkin Lymphoma as presented at ASH 2020
Leslie Popplewell, MD, FACP, on the challenges of delivering CAR T-cell therapy to lymphoma patients
Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, considers the biggest challenges in making CAR T-cell therapies more available to patients with lymphoma
Leslie Popplewell, MD, FACP, on the management of adverse events associated with CAR T-cell therapy
Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, regarding the management of adverse events (AEs) associated with CAR T-cell therapy, specifically prolonged hematologic toxicity
Leslie Popplewell, MD, FACP, describes how engineered toxin bodies work as an anti-cancer treatment
Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, describes how engineered toxin bodies (EBTs) work as an anti-cancer treatment
Leslie Popplewell, MD, FACP, on the future of CAR T-cell therapies in follicular lymphoma
Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, speculates on the future of CAR T-cell therapies in the management of follicular lymphoma and elaborates on results from the Phase II ELARA trial presented at ASH 2020
Leslie Popplewell, MD, FACP, discusses the latest treatment trends in follicular lymphoma
Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, shares perspective on the latest treatment trends in follicular lymphoma
Frederick Locke, MD, shares thoughts on the evolution of bispecific antibodies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, shares thoughts on the evolution of bispecific antibodies
Frederick Locke, MD, speculates on the future of CAR T-cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, offers opinion on the effectiveness and overall direction of CAR T-cell therapies as seen at the 62nd Annual ASH Meeting & Exposition
David Sallman, MD, offers opinion on the most exciting clinical data in AML coming out of ASH 2020
Dr. Sallman, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center, offers opinion on the most exciting clinical progress in acute myeloid leukemia (AML) coming out of the 62nd Annual ASH Meeting & Exposition
Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, tells us about the outcomes of the ZUMA-9 clinical study investigating axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
David Sallman, MD, offers details regarding the clinical investigation of CYAD-01
Dr. Sallman, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center, shares outcomes from the clinical trial evaluating CYAD-01, a first-generation NKG2D CAR T-cell therapy in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) presented at ASH 2020
Frederick Locke, MD, offers impressions of the ZUMA-2 study presented at ASH 2020
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, offers impressions of the ZUMA-2 study investigating brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma presented at ASH 2020
Mazyar Shadman, MD, on the investigation of 3rd-generation CAR T-cell therapies targeting CD20
Dr. Shadman, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, UW School of Medicine, shares outcomes from the Phase I/II trial investigating 3rd-generation CAR T-cell therapies targeting CD20 (MB-106) in B-cell lymphoma and chronic lymphocytic leukemia (CLL) patients presented at ASH 2020
Frederick Locke, MD, summarizes outcomes from the ZUMA-1 clinical trial presented at ASH 2020
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, summarizes outcomes from the ZUMA-1 clinical trial investigating axicabtagene ciloleucel (axi-cel) in patients with refractory large B-cell lymphoma presented at the 62nd Annual ASH Meeting & Exposition
David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia
Dr. Sallman, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center, considers what the presence of an IDH2 mutation tells us about the prognosis of a patient with acute myeloid leukemia (AML)
Mazyar Shadman, MD, on the efficacy & tolerability of zanubrutinib in B-cell malignancies
Dr. Shadman, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, UW School of Medicine, offers impressions of the efficacy and tolerability of zanubrutinib in patients with relapsed/refractory B-cell malignancies who experience intolerance to ibrutinib
David Sallman, MD, elaborates on the first-in-class anti-CD47 antibody magrolimab
Dr. Sallman, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center, tells us about the first-in-class anti-CD47 antibody magrolimab and why this product may be important in the management of acute myeloid leukemia (AML)
Mazyar Shadman, MD, on patients with B-cell malignancies who are intolerant to 1st line ibrutinib
Dr. Shadman, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, UW School of Medicine, considers how often patients with relapsed/refractory B-cell malignancies are intolerant of first-line therapy with ibrutinib
Chaitra Ujjani, MD, speculates on next steps in the investigation of ibrutinib + venetoclax
Dr. Ujjani, Physician, Seattle Cancer Care Alliance, Clinical Associate Professor, Medical Oncology, UW School of Medicine, speculates on next steps in the investigation of combination ibrutinib and venetoclax in relapsed/refractory follicular lymphoma
Chaitra Ujjani, MD, regarding the evolving treatment landscape of follicular lymphoma
Dr. Ujjani, Physician, Seattle Cancer Care Alliance, Clinical Associate Professor, Medical Oncology, UW School of Medicine, considers how the combination of BTK inhibitors and BCL-2 inhibitors fits into the treatment landscape of follicular lymphoma
Chaitra Ujjani, MD, elaborates on the impact of new therapies in follicular lymphoma
Dr. Ujjani, Physician, Seattle Cancer Care Alliance, Clinical Associate Professor, Medical Oncology, UW School of Medicine, elaborates on the impact of new therapies in the treatment of follicular lymphoma
Chaitra Ujjani, MD, considers the efficacy of ibrutinib + venetoclax in relapsed/refractory FL
Dr. Ujjani, Physician, Seattle Cancer Care Alliance, Clinical Associate Professor, Medical Oncology, UW School of Medicine, shares outcomes from Abstract 2943, a study investigating combination ibrutinib and venetoclax in relapsed/refractory follicular lymphoma (FL) presented at ASH 2020
Chaitra Ujjani, MD, regarding the investigation of CLL patients hospitalized with COVID-19
Dr. Ujjani, Physician, Seattle Cancer Care Alliance, Clinical Associate Professor, Medical Oncology, UW School of Medicine, discusses the worldwide research collaboration investigating the clinical experience of patients with chronic lymphocytic leukemia (CLL) who were hospitalized with COVID-19 (Abstract 1590) presented at ASH 2020
Lori Leslie, MD, on real-world outcomes in CLL patients receiving ibrutinib or chemoimmunotherapy
Dr. Leslie, Director, Indolent Lymphoma and Chronic Leukemia Research Programs, John Theurer Cancer Center at Hackensack University Medical Center, discusses real-world outcomes among patients with chronic lymphocytic leukemia (CLL) receiving first-line ibrutinib versus chemoimmunotherapy presented at the 62nd Annual ASH Meeting & Exposition
Lori Leslie, MD, discusses the Phase II Global Unity-NHL trial from ASH 2020
Dr. Leslie, Director, Indolent Lymphoma and Chronic Leukemia Research Programs, John Theurer Cancer Center at Hackensack University Medical Center, tells us about the outcomes of the Phase II Global Unity-NHL trial investigating umbralisib in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL)
Lori Leslie, MD, considers whether ibrutinib + venetoclax is effective in the management of FL
Dr. Leslie, Director, Indolent Lymphoma and Chronic Leukemia Research Programs, John Theurer Cancer Center at Hackensack University Medical Center, considers whether ibrutinib plus venetoclax is an effective combination in the management of refractory follicular lymphoma (FL)
Michael Savona, MD, regarding the ASCEMBL study presented at ASH 2020
Dr. Savona, Professor of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, provides impressions of the Phase III ASCEMBL study investigating asciminib versus bosutinib in patients with chronic myeloid leukemia (CML) presented at ASH 2020
David Siegel, MD, PhD, shares details from the APOLLO & CANDOR trial updates presented at ASH '20
Dr. Siegel, Chief of the Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, offers impressions of the APOLLO and CANDOR trial updates presented at the 62nd Annual ASH Meeting & Exposition
Jennifer Brown, MD, PhD, provides perspective on the side-effect profiles of next-gen BTK inhibitors
Dr. Brown, Director, Chronic Lymphocytic Leukemia Center (CLLC), Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, provides perspective on the side-effect profiles of next-generation BTK inhibitors, particularly cardiac toxicities
David Siegel, MD, PhD, regarding the early test results of CC-220 presented at ASH 2020
Dr. Siegel, Chief of the Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, tells us about the early results of the study of iberdomide (IBER; CC-220) in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/refractory multiple myeloma (RRMM)
Jennifer Brown, MD, PhD, on the addition of zanubrutinib to the NCCN Guidelines for CLL
Dr. Brown, Director, Chronic Lymphocytic Leukemia Center (CLLC), Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explains how and why zanubrutinib was recently added to the NCCN Guidelines for chronic lymphocytic leukemia (CLL)
David Siegel, MD, PhD, elaborates on outcomes from the KarMMa trial
Dr. Siegel, Chief of the Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, elaborates on outcomes from the KarMMa trial investigating BCMA CAR-T cell therapy in elderly and other high-risk relapsed/refractory multiple myeloma (RRMM) presented at ASH 2020
Jennifer Brown, MD, PhD, offers opinion on how zanubrutinib fits into the CLL treatment landscape
Dr. Brown, Director, Chronic Lymphocytic Leukemia Center (CLLC), Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, offers opinion on how zanubrutinib fits into treatment algorithms for chronic lymphocytic leukemia (CLL)
David Siegel, MD, PhD, regarding bispecific antibodies in the management of relapsed/refractory MM
Dr. Siegel, Chief of the Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, regarding bispecific antibodies in the management of relapsed/refractory multiple myeloma (RRMM) after reviewing clinical presentations from the 62nd Annual ASH Meeting & Exposition
Jennifer Brown, MD, PhD, shares outcomes of Arm C of the SEQUOIA trial from ASH 2020
Dr. Brown, Director, Chronic Lymphocytic Leukemia Center (CLLC), Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, shares outcomes of Arm C of the SEQUOIA clinical study investigating zanubrutinib chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma) (SLL) patients with the del(17p) mutation
David Siegel, MD, PhD, summarizes outcomes from the Phase I CRB-402 study presented at ASH 2020
Dr. Siegel, Chief of the Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, offers opinion on BCMA CAR-T cell therapy and summarizes outcomes from the Phase I CRB-402 study, investigating ide-cel (bb21217) in relapsed/refractory multiple myeloma (RRMM) presented at ASH 2020
Jennifer Brown, MD, PhD, considers the unmet needs in patients with CLL or SLL with del(17p)
Dr. Brown, Director, Chronic Lymphocytic Leukemia Center (CLLC), Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, tells us about the role of next-generation BTK inhibitors in the management of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma) (SLL) patients with del(17p)
Lindsey Roeker, MD, on examining the experience of CLL patients hospitalized with COVID-19
Dr. Roeker, Assistant Attending Physician, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the worldwide research collaboration investigating the clinical experience of patients with chronic lymphocytic leukemia (CLL) who were hospitalized with COVID-19 presented at ASH 2020 (Abstract 1590)
Anthony Mato, MD, MSCE, examines different treatment approaches to BTK inhibitor intolerance
Dr. Mato, Director, CLL Program, Memorial Sloan Kettering Cancer Center, considers some of the different treatment approaches for patients who develop BTK inhibitor intolerance
Melissa Alsina, MD, considers the role of anti-BCMA CAR-T cell therapy
Dr. Alsina, Associate Professor of Medicine, Blood and Marrow Transplant Program, Head, Multiple Myeloma Transplant Program, Moffitt Cancer Center, considers how anti-BCMA CAR-T cell therapy may fit into the treatment landscape of relapsed/refractory multiple myeloma (RRMM)
Anthony Mato, MD, MSCE, elaborates on outcomes from the BRUIN trial presented at ASH 2020
Dr. Mato, Director, CLL Program, Memorial Sloan Kettering Cancer Center, regarding outcomes from the BRUIN trial (Abstract 542) investigating the safety and efficacy of the selective, non-covalent BTK inhibitor LOXO-305
Melissa Alsina, MD, shares the long-term follow-up outcomes of the Phase I CRB-402 study
Dr. Alsina, Associate Professor of Medicine, Blood and Marrow Transplant Program, Head, Multiple Myeloma Transplant Program, Moffitt Cancer Center, shares the long-term follow-up outcomes of the Phase I CRB-402 study of idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma (RRMM) patients presented at ASH 2020
Anthony Mato, MD, MSCE, shares some of the key findings on the InformCLL Registry from ASH 2020
Dr. Mato, Director, CLL Program, Memorial Sloan Kettering Cancer Center, shares some of the key findings on the InformCLL Registry reported at the 62nd Annual ASH Meeting & Exposition
Melissa Alsina, MD, offers opinion on anti-BCMA CAR-T cell therapy
Dr. Alsina, Associate Professor of Medicine, Blood and Marrow Transplant Program, Head, Multiple Myeloma Transplant Program, Moffitt Cancer Center, offers opinion on anti-BCMA CAR-T cell therapy in the treatment of hematologic malignancies, particularly multiple myeloma
Anthony Mato, MD, MSCE, tells us about the InformCLL Registry
Dr. Mato, Director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the InformCLL Registry and why it may be an important tool in the management of chronic lymphocytic leukemia (CLL)
Julio Chavez, MD, MS, provides perspective on exciting data in NHL coming out of ASH 2020
Dr. Chavez, Associate Member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the practice-changing potential of various data in non-Hodgkin lymphoma (NHL) presented at the 62nd Annual ASH Meeting & Exposition
Julio Chavez, MD, MS, offers opinion on the significance of BCL10 mutations
Dr. Chavez, Associate Member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, offers opinion on the significance of BCL10 mutations in activated large B-cell lymphoma (DLBCL) and the role of ibrutinib
Julio Chavez, MD, MS, considers the most exciting clinical studies of axi-cel in lymphoma
Dr. Chavez, Associate Member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, regarding the most exciting clinical studies of axicabtagene ciloleucel (axi-cel) in lymphoma
Julio Chavez, MD, MS, shares outcomes from the ZUMA-5 study presented at ASH 2020
Dr. Chavez, Associate Member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, shares outcomes from the Phase II ZUMA-5 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL)
Othman Al-Sawaf, MD, discusses outcomes from the 4-year follow-up of the CLL14 from ASH '20
Dr. Al-Sawaf, Physician, University Hospital of Cologne, Cologne, Germany, discusses outcomes from the 4-year follow-up of the CLL14 trial presented at the 62nd Annual ASH Meeting & Exposition
Julio Chavez, MD, MS, discusses the unique mechanism of action of axicabtagene ciloleucel
Dr. Chavez, Associate Member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the mechanism of action of axicabtagene ciloleucel (axi-cel) and why this may be effective option in the management of indolent non-Hodgkin lymphoma (iNHL)
Othman Al-Sawaf, MD, on the role of MRD in the management of CLL as a result of data from ASH 2020
Dr. Al-Sawaf, Physician, University Hospital of Cologne, Cologne, Germany, considers the role of minimal residual disease (MRD) in the management of newly diagnosed chronic lymphocytic leukemia (CLL) as a result of the CLL114 trial presented at the 62nd Annual ASH Meeting & Exposition
Julio Chavez, MD, MS, regarding the typical treatment algorithms for relapsed/refractory iNHL
Dr. Chavez, Associate Member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, tells us about typical treatment algorithms for relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and the unmet medical need in these patients
Othman Al-Sawaf, MD, on potential safety concerns associated with venetoclax combinations
Dr. Al-Sawaf, Physician, University Hospital of Cologne, Cologne, Germany, regarding potential safety concerns when treating newly diagnosed chronic lymphocytic leukemia (CLL) patients with the venetoclax plus obinutuzumab or other venetoclax combinations
Yi Lin, MD, PhD, shares impressions of the APOLLO study in relapsed/refractory MM from ASH 2020
Dr. Lin, Consultant, Division of Hematology, Division of Experimental Pathology, Assistant Professor of Oncology, Mayo Clinic, shares impressions of the APOLLO study, investigating the addition of subcutaneous daratumumab to pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Othman Al-Sawaf, MD, regarding the standard of care for first-line treatment of newly diagnosed CLL
Dr. Al-Sawaf, Physician, University Hospital of Cologne, Cologne, Germany, offers opinion on the standard of care for first-line treatment of newly diagnosed chronic lymphocytic leukemia (CLL)
Yi Lin, MD, PhD, on how anti-BCMA CAR-T cell therapy fits into the treatment of RRMM
Dr. Lin, Consultant, Division of Hematology, Division of Experimental Pathology, Assistant Professor of Oncology, Mayo Clinic, provides perspective on how anti-BCMA CAR-T cell therapy fits into the treatment landscape of relapsed/refractory multiple myeloma (RRMM)
Sattva Neelapu, MD, shares highlights in the development of CAR T-cell therapies in lymphoma
Dr. Neelapu, Professor and Deputy Chair, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, tells us about the highlights in the development of CAR T-cell therapies in lymphoma as presented at the 62nd Annual ASH Meeting & Exposition
Yi Lin, MD, PhD, offers opinion on anti-BCMA CAR-T cell therapy
Dr. Lin, Consultant, Division of Hematology, Division of Experimental Pathology, Assistant Professor of Oncology, Mayo Clinic, offers opinion on anti-BCMA CAR-T cell therapy as a promising option in the treatment of hematologic malignancies
Sattva Neelapu, MD, elaborates on long-term results from the ZUMA-1 trial
Dr. Neelapu, Professor and Deputy Chair, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, elaborates on the long-term response in patients treated with axicabtagene ciloleucel (axi-cel) as part of the ZUMA-1 trial
Peter Voorhees, MD, offers opinion on the role of daratumumab as more trial data emerges
Dr. Voorhees, Professor of Medicine, Director of Outreach, Hematologic Malignancies, Atrium Health’s Levine Cancer Institute, offers opinion on the role of daratumumab as more trial data emerges, particularly the updated analysis of the GRIFFIN trial presented at ASH 2020
Sattva Neelapu, MD, discusses advancements in the management of CAR T-cell therapy AEs
Dr. Neelapu, Professor and Deputy Chair, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, discusses advancements in the identification and management of CAR T-cell therapy adverse events (AEs)
Yi Lin, MD, PhD, discusses the unique mechanism of action of ide-cel
Dr. Lin, Consultant, Division of Hematology, Division of Experimental Pathology, Assistant Professor of Oncology, Mayo Clinic, tells us about the mechanism of action of idecabtagene vicleucel (ide-cel) and how it differs from other immuno‑oncology (I-O) and CAR-T cell therapies
Sattva Neelapu, MD, speculates on the future of first-line CAR T-cell therapy in lymphoma
Dr. Neelapu, Professor and Deputy Chair, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, speculates on the future of first-line CAR T-cell therapy in lymphoma as a result of the ZUMA-12 trial
Peter Voorhees, MD, on progress with BCMA-targeted therapies and the challenge of relapse
Dr. Voorhees, Professor of Medicine, Director of Outreach, Hematologic Malignancies, Atrium Health’s Levine Cancer Institute, discusses the progress with BCMA-targeted therapies and the challenge of relapse
Sattva Neelapu, MD, discusses details of the ZUMA-12 trial presented at ASH 2020
Dr. Neelapu, Professor and Deputy Chair, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, tells us about the interim analysis from the ZUMA-12 trial and what differentiates this study from ZUMA-1 and ZUMA-2
Michael Jain, MD, PhD, provides an update on the progress of the ZUMA-11 trial
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, provides an update on the progress of the ZUMA-11 trial and what we're learning about overcoming resistance to CAR T-cell therapy
Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, elaborates on Abstract 1451 presented at the 62nd Annual ASH Meeting & Exposition and considers what we're learning about 'out of specification' CAR T-cell products
Michael Jain, MD, PhD, speculates on exciting studies of immunotherapy in lymphoma
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, speculates on the most exciting ongoing studies of immunotherapy in lymphoma
Michael Jain, MD, PhD, discusses the management of CAR T-cell therapy adverse events
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, discusses the progress in managing CAR T-cell therapy adverse events, specifically cytokine release syndrome (CRS) toxicity and venous thromboembolism (VTE)
Michael Jain, MD, PhD, on immunotherapy treatment trends in the management of aggressive lymphomas
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, shares some of the latest immunotherapy treatment trends in the management of aggressive lymphomas
Michael Savona, MD, considers the practice-changing potential of the ASCERTAIN study
Dr. Savona, Professor of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, considers whether the ASCERTAIN study could change the way we treat myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML)
Stephen Ansell, MD, PhD, elaborates on treatment considerations in Waldenstrom macroglobulinemia
Dr. Ansell, Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic, Minnesota, elaborates on key treatment considerations in patients with Waldenstrom macroglobulinemia (WM) as characterized in Abstract 1141 from the 62nd Annual ASH Meeting & Exposition
Michael Savona, MD, discusses outcomes from the ASCERTAIN trial presented at ASH 2020
Dr. Savona, Professor of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, offers impressions of the ASCERTAIN study investigating oral decitabine/cedazuridine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML)
Peter Voorhees, MD, regarding current controversies in the treatment of multiple myeloma
Dr. Voorhees, Professor of Medicine, Director of Outreach, Hematologic Malignancies, Atrium Health’s Levine Cancer Institute, discusses some of the current controversies in the treatment of multiple myeloma
Michael Savona, MD, elaborates on the role of cytidine deaminase (CDA)
Dr. Savona, Professor of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, shares why rapid degradation of hypomethylating agents (HMAs) or DNA methyltransferase inhibitors (DNMTi) such as decitabine or azacitidine by cytidine deaminase (CDA) is important when managing myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) patients
Stephen Ansell, MD, PhD, elaborates on bridging therapy for lymphoma patients
Dr. Ansell, Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic, Minnesota, describes the Mayo Clinic’s experience with bridging therapy for lymphoma patients before CAR-T cell infusion as reported in Abstract 1222 from the 62nd Annual ASH Meeting & Exposition
Peter Voorhees, MD, discusses some of the current approaches to dealing with daratumumab resistance
Dr. Voorhees, Professor of Medicine, Director of Outreach, Hematologic Malignancies, Atrium Health’s Levine Cancer Institute, discusses some of the current approaches to dealing with daratumumab resistance
Stephen Ansell, MD, PhD, speculates on promising new treatment combinations in follicular lymphoma
Dr. Ansell, Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic, Minnesota, speculates on promising new treatment combinations in follicular lymphoma
Peter Voorhees, MD, regarding the treatment landscape in newly diagnosed & relapsed/refractory MM
Dr. Voorhees, Professor of Medicine, Director of Outreach, Hematologic Malignancies, Atrium Health’s Levine Cancer Institute, provides perspective on the current treatment landscape in newly diagnosed and relapsed/refractory multiple myeloma (MM)
Stephen Ansell, MD, PhD, on options for lymphoma patients who are refractory to CAR T-cell treatment
Dr. Ansell, Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic, Minnesota, tells us about some of the treatments under investigation for lymphoma patients who are refractory to CAR T-cell treatment
Stephen Ansell, MD, PhD, describes the landscape of immunotherapy approaches in lymphoma
Dr. Ansell, Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic, Minnesota, describes the landscape of immunotherapy approaches in lymphoma and some of the barriers that have limited the success of those therapies
Thomas Martin, MD, speculates on the future of the IKEMA study in relapsed multiple myeloma
Dr. Martin, Clinical Professor of Medicine, Interim Chief of Hematology, Helen Diller Family Comprehensive Cancer Center, UCSF, speculates on the future of the IKEMA study, a Phase III trial investigating isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (MM)
Bhavana Bhatnagar, DO, on the design of clinical trials and the representation of minority patients
Dr. Bhatnagar, Associate Professor, Internal Medicine, Division of Hematology, The Ohio State University, considers the implications of the study on racial disparities in the treatment of acute myeloid leukemia (AML) on the design of clinical trials and the representation of minority patients
Bhavana Bhatnagar, DO, shares key takeaways for clinicians regarding racial disparities in AML
Dr. Bhatnagar, Associate Professor, Internal Medicine, Division of Hematology, The Ohio State University, shares key takeaways for clinicians regarding racial disparities in the treatment of acute myeloid leukemia (AML)
Thomas Martin, MD, shares thoughts on minimal residual disease as an indicator of response in MM
Dr. Martin, Clinical Professor of Medicine, Interim Chief of Hematology, Helen Diller Family Comprehensive Cancer Center, UCSF, shares thoughts on minimal residual disease (MRD) as an endpoint or indicator of response in multiple myeloma (MM)
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from ASH 2020
Dr. Bhatnagar, Associate Professor, Internal Medicine, Division of Hematology, The Ohio State University, tells us about the study on racial disparities in the treatment of acute myeloid leukemia (AML) presented at the 62nd Annual ASH Meeting & Exposition
Thomas Martin, MD, talks safety concerns regarding isatuximab plus carfilzomib and dexamethasone
Dr. Martin, Clinical Professor of Medicine, Interim Chief of Hematology, Helen Diller Family Comprehensive Cancer Center, UCSF, offers opinion on safety concerns regarding combination isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (MM)
Bhavana Bhatnagar, DO, on the significance of examining racial disparities in the treatment of AML
Dr. Bhatnagar, Associate Professor, Internal Medicine, Division of Hematology, The Ohio State University, regarding the significance of examining racial disparities in the treatment of acute myeloid leukemia (AML) and discusses additional research on these issues
Thomas Martin, MD, considers the significance of the IKEMA study
Dr. Martin, Clinical Professor of Medicine, Interim Chief of Hematology, Helen Diller Family Comprehensive Cancer Center, UCSF, considers the significance of the IKEMA study and how it impacts the today's multiple myeloma (MM) treatment landscape
Bhavana Bhatnagar, DO, on unexpected findings from a study of racial disparities in treatment of AML
Dr. Bhatnagar, Associate Professor, Internal Medicine, Division of Hematology, The Ohio State University, discusses unexpected findings from a study regarding racial disparities in the treatment of acute myeloid leukemia (AML) presented at ASH 2020, including the absence of some well-established mutational features (i.e. TP53 mutations)
Thomas Martin, MD, discusses outcomes from the Phase III IKEMA study in relapsed MM from ASH 2020
Dr. Martin, Clinical Professor of Medicine, Interim Chief of Hematology, Helen Diller Family Comprehensive Cancer Center, UCSF, shares outcomes from the IKEMA study, a Phase III study investigating isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (MM)
Lori Leslie, MD, discusses outcomes from the Phase II ZUMA-5 study presented at ASH 2020
Dr. Leslie, Director, Indolent Lymphoma and Chronic Leukemia Research Programs, John Theurer Cancer Center at Hackensack University Medical Center, offers opinion on axicabtagene ciloleucel (axi-cel), a promising agent in the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), and discusses outcomes from the Phase II ZUMA-5 study presented at ASH 2020
Leslie Popplewell, MD, provides perspective on the ELARA study investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies
Dr. Popplewell, Clinical Associate Professor, City of Hope, provides perspective on the ELARA study presented at ASCO20 and EHA20 investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies
Leslie Popplewell, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat
Dr. Popplewell, Clinical Associate Professor, City of Hope, provides thoughts on the unique MOA of the newly FDA approved tazemetostat (Tazverik) and how this product may evolve in the management of follicular lymphoma
Leslie Popplewell, MD, provides thoughts on the role Yescarta (axicabtagene ciloleucel) will play in low grade NHL management
Dr. Popplewell, Clinical Associate Professor, City of Hope, provides thoughts, based on the evidence presented at ASCO20, on the role Yescarta (axicabtagene ciloleucel) will play in the management of low grade non-Hodgkin lymphoma (NHL)
Leslie Popplewell, MD, on impressions of the Alexander trial investigating AUTO3(CAR-T cell therapy) as DLBCL treatment
Dr. Popplewell, Clinical Associate Professor, City of Hope, shares impressions of the Alexander trial investigating AUTO3 (CAR-T cell therapy) as a treatment for diffuse large B-cell lymphoma (DLBCL)
Leslie Popplewell, MD, discusses the potential practice changing outcomes of the Keynote-204 study presented at ASCO20
Dr. Popplewell, Clinical Associate Professor, City of Hope, discusses potential practice changing outcomes of the Keynote-204 study presented at ASCO20 investigating pembrolizumab versus brentuximab vedotin in classical Hodgkin lymphoma
Andrew Zelenetz, MD, describes the study presented at ASCO 20 exploring the CIBMTR analysis of PET scans
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, describes the clinical study presented at ASCO20 exploring the CIBMTR analysis of PET scans and the role of PET scans in the management of lymphoma
Andrew Zelenetz, MD, discusses the validity and availability of the EZH2 companion diagnostic test
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, discusses the validity and availability of the EZH2 companion diagnostic test at Memorial Sloan Kettering Cancer Center and the broader availability for other lymphoma treating physicians
Andrew Zelenetz, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, provides thoughts on the unique MOA of the newly FDA approved tazemetostat (Tazverik) and how this product may evolve in the management of follicular lymphoma
Andrew Zelenetz, MD, shares some of the unique aspects in the clinical design of the BOVen study
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, shares some of the unique aspects in the clinical design of the BOVen study as the primary investigator
Andrew Zelenetz, MD, examines whether Yescarta (axicabtagene ciloleucel) will play a significant role in low grade NHL management
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, examines whether Yescarta (axicabtagene ciloleucel) will play a significant role in the management of low grade non-Hodgkin lymphoma (NHL) based on evidence presented at ASCO 20
Andrew Zelenetz, MD, shares impressions of the Alexander trial investigating AUTO3 as treatment for DLBCL
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, shares impressions of the Alexander trial investigating AUTO3 (CAR-T cell therapy) as treatment for diffuse large B-cell lymphoma (DLBCL)
Andrew Zelenetz, MD, provides thoughts on the potential practice changing outcomes of the Keynote-204 study
Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, provides thoughts on the potential practice changing outcomes of the Keynote-204 study
Constantine Tam, MD, & Robert Figlin, MD, FACP, discuss progress in Waldenstrom’s Macroglobulinemia & ASCO20
Constantine Tam, MD, of Peter MacCallum Cancer Centre and Robert Figlin, MD, FACP, of Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center discuss recent clinical progress in the management of Waldenstrom macroglobulinemia including management with BTK inhibitors and clinical presentations at ASCO20
Follow @OBRTweets